It is clear that for a year that the company has been robbing Peter to pay Paul; not really an unusual situation where a breakthrough drug is being tested and developed. This word of this particular financing deal should neither alarm nor enthuse. Everything is dependent on a material step in getting the NGIO IPO launched and IND approval of the drug. As the stock value increases, costly debt can be refinanced.